Identification of risk factors for resistant Pseudomonas aeruginosa infections with or without ESBL among hospitalized patients and developments and validation of a risk predictive tool

This study aims to develop a clinical risk prediction tool for antibiotic resistant Pseudomonas infections among inpatients.

Principal Investigator:

Sara Yee Tartof, PhD, MPH

Funding Source:

Merck & Co., Inc.

Funding Years:

2016 - 2019